The HDPCR NSCLC assay delivers results within 24 hours. Credit: kalhh from Pixabay.

ChromaCode has entered a strategic partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.

To be available through an early access programme, the assay leverages ChromaCode’s High Definition PCR (HDPCR) multiplexing technology.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Delivering results in under 24 hours, the HDPCR NSCLC assay can help identify all National Comprehensive Cancer Network (NCCN) recommended variants in one multiplexed assay.

It has been developed for very low concentrations, needing just 15 nanograms (ng) of input DNA and 5ng of RNA.

The assay showed more than 99% coverage of target genes and a 99% concordance with next-generation sequencing, making it a better option over biomarker testing, noted ChromaCode.

Protean president and CEO Anthony Magliocco said: “We value the rapid turnaround and clinically relevant markers of the HDPCR NSCLC assay. We see a real opportunity to collaborate with commercial payors, US Department of Veterans Affairs, and other government agencies, to establish coverage and reimbursement for this revolutionary technology.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

HDPCR is an advanced approach for multiplexing biomarkers in a single, rapid assay across multiple sample types.

Implemented on ChromaCode’s cloud-based analysis platform, the HDPCR technology is suitable for use in various applications including transplant, oncology, minimal residual disease and non-invasive prenatal testing.

ChromaCode chief business officer Padma Sundar said: “This partnership aligns with our mission to increase the availability of advanced diagnostic technologies, ensuring that medical laboratories have access to cutting-edge tools that can transform the landscape of cancer care.”

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now